Poor growth in medical sales for Beiersdorf:
This article was originally published in Clinica
Executive Summary
Sales at the medical division of Beiersdorf (Germany) grew only 0.6% to DM 878 million ($593 million) in the nine months ended September 30th, 1995, compared with last year. Total turnover at Beiersdorf rose 3.2% to DM 4,077 million. At constant exchange rates sales growth would have been over 7% but the strength of the DM pushed this figure down. Domestic sales rose 7.2% to DM 1,535 million and exports increased 0.9% to DM 2,541 million. In the first nine months profits grew slightly faster than turnover. The company forecasts stronger full-year turnover growth than in the first nine months. Full-year profits are also predicted to rise at a greater rate than turnover.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.